English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Tools annual

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Presents the access of premium content as premium feature

Premium Content

Global: Zendy Plus annual

Global: Zendy Free Plan

Introduction: Invasive sinus aspergillosis infection has been reported with increasing frequency in the last decade, especially, inimmunocompromised patients with chronic invasive sinus aspergillosis (CISA). The gold standard for treatment has been wide surgicaldebridement, intravenous administration of antifungal agents, such as amphotericin B, but the prognosis remains poor. Newer antifungalagents are being tried but no standard treatment option with new antifungal agents has yet been established for chronic invasive fungalsinusitis. Therefore, we undertook this study to evaluate the efficacy of voriconazole in patients of chronic invasive sinus aspergillosis.Materials and methods: This study is a prospective randomized unblinded study with primary aim of evaluating the feasibility and effectivityof voriconazole in patients of chronic invasive sinus aspergillosis with intraorbital or intracranial extension, and secondarily to comparevoriconazole with amphotericin B therapy in patients with chronic invasive sinus aspergillosis.Observations and results: Thirty-three patients who fulfilled the eligibility criteria were included in this study. There were 18 patients enrolledin group I who received amphotericin therapy and 15 patients in group II who received voriconazole therapy. Out of 33 patients, 9 patientshad complete response, 10 had partial response, in eight patients disease became stable and there were seven failures. Overall 50%patients had a successful outcome in group I, whereas 60% had a successful outcome in group II receiving oral voriconazole. On comparingonly in extradural group, 5/10 had a successful outcome in group I receiving amphotericin B, whereas 8/12 (66.7%) had a successfuloutcome in group 2 receiving voriconazole. There was significant difference between adverse reactions of the two drugs, with amphotericinB having a significant renal and cardiotoxicity as compared to voriconazole; though patients on voriconazole developed skin rashes whichwere transient and disappeared on completion of the therapy.Conclusion: The present series demonstrates that oral voriconazole can be the primary line of therapy in chronic invasive sinus aspergillosisin carefully monitored immunocompetent cases. Multicentric, randomized studies are required to define disease definition, duration andsuccessful outcome.

Should Voriconazole be the Primary Therapy for Chronic Invasive Sinus Aspergillosis (CISA)?